These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19308936)

  • 1. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
    Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
    J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
    Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
    PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
    Wesierska-Gadek J; Borza A; Komina O; Maurer M
    Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J; Schmid G
    Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
    Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
    J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
    Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
    Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
    Ljungman M; Paulsen MT
    Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Schmitz ML; Ranftler C
    J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
    Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
    Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
    Wesierska-Gadek J; Gueorguieva M; Horky M
    Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
    Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
    Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
    Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
    Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells.
    David-Pfeuty T; Nouvian-Dooghe Y; Sirri V; Roussel P; Hernandez-Verdun D
    Oncogene; 2001 Sep; 20(42):5951-63. PubMed ID: 11593402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
    Mohapatra S; Chu B; Zhao X; Pledger WJ
    Cancer Res; 2005 Sep; 65(17):7717-23. PubMed ID: 16140939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
    Kotala V; Uldrijan S; Horky M; Trbusek M; Strnad M; Vojtesek B
    Cell Mol Life Sci; 2001 Aug; 58(9):1333-9. PubMed ID: 11577989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.